Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRAX 
Praxis Precision Medicines Inc (PRAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: PRAX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $97.67
1 Year Target Price $97.67
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.76% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 952.45M USD | Price to earnings Ratio - | 1Y Target Price 97.67 |
Price to earnings Ratio - | 1Y Target Price 97.67 | ||
Volume (30-day avg) 12 | Beta 2.62 | 52 Weeks Range 26.70 - 91.83 | Updated Date 07/9/2025 |
52 Weeks Range 26.70 - 91.83 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2868.84% |
Management Effectiveness
Return on Assets (TTM) -39.95% | Return on Equity (TTM) -63.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 625528598 | Price to Sales(TTM) 117.27 |
Enterprise Value 625528598 | Price to Sales(TTM) 117.27 | ||
Enterprise Value to Revenue 77.02 | Enterprise Value to EBITDA -6.86 | Shares Outstanding 20369000 | Shares Floating 15702041 |
Shares Outstanding 20369000 | Shares Floating 15702041 | ||
Percent Insiders 0.16 | Percent Institutions 122.02 |
Upturn AI SWOT
Praxis Precision Medicines Inc
Company Overview
History and Background
Praxis Precision Medicines, Inc. is a biopharmaceutical company focused on translating genetic insights into therapies for central nervous system (CNS) disorders. Founded in 2015, it aims to address unmet medical needs in neurological and psychiatric diseases.
Core Business Areas
- Neurology: Focuses on developing therapies for epilepsy and other neurological disorders.
- Psychiatry: Develops treatments for psychiatric conditions such as depression and anxiety.
Leadership and Structure
The leadership team consists of experienced executives in drug development and commercialization. The organizational structure includes research, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- PRAX-19: An extra-synaptic selective inhibitor in Phase 2 clinical trials for treatment-resistant depression (TRD). Competitors include Johnson & Johnson (Spravato), Sage Therapeutics (Zuranolone).
- PRAX-628: A next-generation selective NaV6 channel inhibitor being developed for epilepsy. In Phase 2 clinical trials. Competitors include UCB (Briviact), SK Life Science (Xcopri).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and patent protection. The CNS market is competitive with many established players and emerging companies.
Positioning
Praxis Precision Medicines is positioning itself as a leader in precision medicines for CNS disorders, focusing on genetically validated targets and novel therapeutic approaches.
Total Addressable Market (TAM)
The TAM for CNS disorders is substantial, estimated to be billions of dollars annually. Praxis is positioned to capture a portion of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Strong pipeline of CNS therapies
- Focus on precision medicine approach
- Experienced management team
Weaknesses
- Limited revenue generation
- Dependence on clinical trial outcomes
- High cash burn rate
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new CNS indications
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established players
Competitors and Market Share
Key Competitors
- SAGE
- JNJ
- LLY
Competitive Landscape
Praxis faces competition from established pharmaceutical companies and emerging biotech firms. Its advantage lies in its precision medicine approach and focus on genetically validated targets. Disadvantages include limited resources and the risks associated with clinical development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development of its pipeline candidates.
Future Projections: Future growth is contingent on successful clinical trial outcomes, regulatory approvals, and commercial launch of its therapies. Analyst estimates vary based on pipeline progress.
Recent Initiatives: Recent initiatives include advancing its lead drug candidates through clinical trials, securing partnerships, and strengthening its intellectual property portfolio.
Summary
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for CNS disorders using a precision medicine approach. While they have a promising pipeline and experienced management, they face risks associated with clinical trials, regulatory approvals, and competition. Their future success hinges on positive clinical trial results and strategic partnerships. Given its current stage, the company's revenue streams are minimal, relying on future product commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. The information is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be made based on individual risk tolerance and financial circumstances.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Praxis Precision Medicines Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-16 | President, CEO & Director Mr. Marcio Silva De'Souza M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | Website https://praxismedicines.com |
Full time employees 116 | Website https://praxismedicines.com | ||
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.